Multinational Pharma Companies Accelerate China Market Entry with Dual Strategic Approaches

　　【Pharmaceutical Network Market Analysis】Since 2022, many large multinational pharmaceutical companies, such as Pfizer, Sanofi, Amgen, and Gilead, have accelerated their strategic transformation and upgrading, as well as initiated a new wave of mergers and acquisitions. Among them, the Chinese market is one of the key focuses for many enterprises.
 

On October 28, Novartis established the Hainan Office and Real-World Research Center in the Boao Lecheng International Medical Tourism Pilot Zone, further upgrading its strategic cooperation with the Lecheng Pilot Zone. This move aims to promote collaboration and exchange in real-world research and clinical drug development, while advancing the progress of translational medicine in Hainan and fostering related talent cultivation. While accelerating the availability of more innovative drugs to benefit patients in China sooner, it also supports the development of China's healthcare industry.
 

It is reported that Novartis was one of the earliest multinational pharmaceutical companies to cooperate with Lecheng Pilot Zone. Currently, six innovative overseas specialty drugs from Novartis have been launched in Boao Lecheng, and eight Novartis innovative drugs have been included in Lecheng Global Specialty Drug Insurance. The industry believes that the establishment of Novartis Hainan Office and Real-World Research Center marks a new milestone in the cooperation between Novartis and Boao Lecheng.
 

AstraZeneca, together with CICC Capital and Wuxi Guolian Group, announced on August 4 a cooperation intention to establish a fund with a total scale of 5 billion yuan, with the first phase raising 1 billion yuan.
 

The above-mentioned cooperation in fundraising represents the second phase of capital raising for the AstraZeneca CICC Healthcare Industry Fund. This fund is built upon AstraZeneca's industry resources and CICC Capital's financial resources, further integrating Wuxi Guolian Group's regional advantages and comprehensive financial service capabilities in the local area. Notably, within just over a year since its establishment, the AstraZeneca CICC Healthcare Industry Fund has already invested in 10 innovative healthcare companies.
 

Of course, in addition to continuous investment in the Chinese market, cooperation between multinational pharmaceutical companies and Chinese pharmaceutical enterprises has become increasingly common this year. For instance, in early August, Sanofi reached a collaboration with Innovent Biologics based in Suzhou, including an initial strategic equity investment of 300 million euros (equivalent to RMB 2.07 billion) in the latter.
 

Notably, as most companies are seeking changes to adapt to market development and accelerating the adjustment of their strategic layouts, their personnel adjustments are also becoming more frequent. Since 2022, several multinational pharmaceutical companies, including Pfizer, Novartis, Sanofi, and Merck, have undergone organizational and personnel changes in their China operations.
 

According to incomplete statistics, as of August this year, at least eight senior executives from the China divisions of large multinational pharmaceutical companies have stepped down, averaging one departure per month. In terms of new executive appointments, there have been 24 personnel changes. Notably, several former executives from multinational pharmaceutical companies have joined local Chinese pharmaceutical firms. For example, Wu Kun, formerly Chief Operating Officer of Pfizer's China division, joined Jixing Pharmaceuticals as Chief Commercial Officer; Xia Shaofei (Summer Xia), previously head of Novartis' Hematology Division, joined Haisen Biopharmaceuticals as Chief Executive Officer...
 

Industry analysis suggests that the above-mentioned actions of major multinational pharmaceutical companies reflect their ongoing evaluation of strategies, contemplating how to position their businesses in China, and are taking proactive steps. Overall, multinational pharmaceutical companies currently adopt two different strategies. Some aim to further cultivate the Chinese market, continuously introducing more best-in-class and innovative drugs and therapies. These companies may expand further in China, adding new businesses and investing in new business models.
 

Another group of multinational pharmaceutical companies are focused on how to better balance expectations with future risks in the Chinese market. Their strategies increasingly involve collaboration with Chinese pharmaceutical companies, technology transfers (license-out), and other forms of cooperation or joint ventures to better manage uncertainties in the Chinese market.
 

But no matter which approach is adopted, with the medical needs of Chinese residents yet to be met and China's healthcare industry developing rapidly, multinational pharmaceutical companies will continue to accelerate their expansion in the Chinese market. However, they are expected to more prudently and seriously review their future strategic plans in China while continuing to deepen their innovative capabilities.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.